Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1Phase 1 1

Status

Completed 4Unknown 1Active not recruiting 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

Other hematologic neoplasm 6Lymphoid 6

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 87Lymphoma, Non-Hodgkin 72Lymphoma 63Lymphoma, Follicular 59Lymphoma, Mantle-Cell 58Lymphoma, Large B-Cell, Diffuse 40Multiple Myeloma 36Hodgkin Disease 32Recurrence 29Lymphoma, B-Cell, Marginal Zone 28Lymphoma, B-Cell 19Leukemia 18Waldenstrom Macroglobulinemia 14Neoplasms 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Neoplasms, Plasma Cell 8Lymphoma, T-Cell 7Leukemia, Myeloid, Acute 7Burkitt Lymphoma 7Lymphoma, T-Cell, Peripheral 6Leukemia, B-Cell 6Hematologic Neoplasms 6Sezary Syndrome 5Myelodysplastic Syndromes 5Mycosis Fungoides 5Immune System Diseases 5Small Cell Lung Carcinoma 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, Large-Cell, Anaplastic 4

Interventions

Cyclophosphamide 17ofatumumab 14fludarabine 11Rituximab 11ibrutinib 10fludarabine phosphate 9acalabrutinib 7Lenalidomide 6Bendamustine Hydrochloride 6venetoclax 5obinutuzumab 5Vincristine 4Mesna 4Melphalan 4Immunotherapy, Adoptive 4pirtobrutinib 3Whole-Body Irradiation 3Mycophenolic Acid 3Chlorambucil 3Bortezomib 3Alemtuzumab 3spebrutinib 2navitoclax 2idelalisib 2Tacrolimus 2Tablets 2Stem Cell Transplantation 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2KW-2478 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Leukemia, B-Cell × Bendamustine Hydrochloride × Clear all
NCT04515238 2025-06-10

CLL2-BZAG

German CLL Study Group

Phase 2 Active not recruiting
42 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell

NCT03787264 2024-12-30

CLL2-BAAG

German CLL Study Group

Phase 2 Completed
46 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell

NCT02689141 2020-06-11

Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)

German CLL Study Group

Phase 2 Completed
66 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01400685 2018-01-25

Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL

Massachusetts General Hospital

Phase 1 Completed
34 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01520922 2017-01-19

Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)

Novartis

Phase 2 Completed
99 enrolled 27 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoid, Neoplasms, Recurrence, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01678430 2012-10-15

RIAltO

University of Liverpool

Phase 3 Unknown
670 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡